快捷导航

南科大医学院
官方公众号

The First Trans-Guangdong-Hong Kong-Macau Bay Area Symposium on Translational Cancer Medicine held

更新时间:2017-12-06

The first trans-Guangdong-Hong Kong-Macau Bay Area Symposium on Translational Cancer Medicine was held in Shenzhen from December 1 - 3 2017.

The theme of the forum was on "Cooperation, Innovation, Precision, and Translation." It was sponsored by the South University of Science and Technology School of Medicine (in preparation), Shenzhen University School of Medicine and Chinese Academy of Medical Sciences Cancer Hospital, Shenzhen.

Wu Chuanyue, vice president of Southern University of Science and Technology, and Luo Lexuan, director of the Shenzhen Municipal Health and Family Planning Commission attended the opening ceremony of the forum.

The opening ceremony was presided over by Zhang Jian, executive director of Preparatory Office of Southern Medical University Medical School and executive chairman of Forum Organizing Committee.

图片5.png

meeting venue


图片6.png 

Wu Chuanyue’s speech

Wu Chuanyue welcomed and thanked experts and scholars who attended the symposium. He expressed hope that the forum will further promote the layout and development of tumor research in the Bay Area. Through this platform, experts from all over the world will be provided opportunities to exchange ideas and strengthen their cooperation.

图片7.png


Luo Le Xuan's speech 

At the conference, Luo Lexuan emphasized that Shenzhen places great importance to the development of the health care industries and enterprises. Through the forum, he hoped to establish closer cooperation and hear the insights offered by the experts.

1512523856458073875.jpg

Zhang Jian presided over the opening ceremony.

Nearly a hundred experts in the field of basic medicine, clinical medicine, and translational medicine gathered in the three-day forum to share the in the latest research and exciting achievements.

The successful hosting of the conference has promoted the cooperation among the top scientists from Guangdong, Hong Kong SAR and Macao SAR, Mainland China, and Singapore. It will greatly promote the development of the field of cancer conversion medicine.